Business Wire

Americhem Unveils 2024 Sustainability Report Highlighting Major Accomplishments

5.12.2024 16:00:00 CET | Business Wire | Press release

Share

Report Showcases Company’s Commitment to Environmental Responsibility, Highlights Future Ambitions

Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, proudly announces the release of its 2024 Sustainability Report. This comprehensive report, titled Embracing Our Tomorrow, highlights Americhem’s unwavering commitment to environmental and social responsibility, providing an in-depth look at the company’s efforts across the entire value chain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205637181/en/

Lauren Lutikoff, Americhem Global Sustainability Leader (Photo: Business Wire)

Following the recent award of the Silver EcoVadis Medal, which places Americhem among the top 15% of companies assessed by EcoVadis—a globally recognized platform that rates businesses’ sustainability in various categories including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. Americhem’s sustainability report showcases the company’s major accomplishments and outlines future ambitions, including:

Americhem 2030 Plan: Over the past few years, Americhem has established baseline performance metrics and set targets within the business for each key pillar, aligning with the UN Sustainable Development Goals and Americhem’s vision for sustainability. The plan outlines the company’s dedication to advancing operations, developing sustainable solutions, and empowering employees, all while contributing to the communities in which it operates.

Americhem Decarbonization Strategy: The report reveals a robust decarbonization strategy focused on renewable energy, waste handling, and resource conservation projects at Americhem’s facilities. Other actions include increasing collaborative efforts with suppliers and customers to reduce greenhouse gas emissions.

“Meeting the sustainability goals of our customers requires the same mindset—embracing change while meeting the high-quality standards that consumers demand. Embarking on our sustainability journey is more than just a commitment; it’s a pledge for the future. Our mission is to lead with integrity, innovate responsibly, and inspire progress,” said John Richard, CEO at Americhem.

Major Accomplishments Built on Three Critical Pillars

Americhem’s sustainable framework is built on three critical pillars: People, Process, and Product. In 2024, Americhem rolled out programs and launched new products that contributed to these pillars, including:

People: Americhem’s commitment to world-class safety is demonstrated through its “Next Level Safety” campaign. The company has significantly surpassed industry benchmarks, with a Total Recordable Incident Rate (TRIR) 22% below the industry average.

Process: Americhem announced it is now sourcing 100% electricity through a local renewable energy program for its World Headquarters location. This transition is estimated to avoid approximately 750 metric tons of CO2 emissions annually1, equivalent to the carbon sequestered by 875 acres of U.S. forests in one year2.

Product: Americhem continues to lead in innovation with new product offerings such as the EcoLube™ line of PFAS-free internally lubricated compounds, addressing industry challenges around proposed PFAS regulations and promoting environmental responsibility.

Lauren Lutikoff, Americhem’s Global Sustainability Leader, said, “Americhem’s initiatives are aligned with the company’s commitment to innovation, while continually advancing environmental responsibility and product safety.”

“In today’s world, operating sustainably is no longer a choice, but a necessity. At Americhem, we recognize that sustainability is fundamental to our future and the well-being of our planet. This report is not just an accounting of our accomplishments, but rather a path for continued improvement and a testament of our dedication to a better tomorrow,” added Lutikoff.

To read Americhem’s sustainability report, visit www.americhem.com/pages/sustainability.

About Americhem

Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.

1Calculation based on City of Cuyahoga Falls’ Utility Department Emissions Factor Rating for 2022 and Americhem Global Headquarters’ annual electricity consumption data.

2Calculation based on the EPA’s Greenhouse Gas Equivalency Calculator (https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator#results)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205637181/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye